This study is currently recruiting.

Description:  A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphates in Children and Adolescents with Osteogenesis Imperfecta

Eligibility & Criteria

IRB #:  IRB00397371

Principal Investigator: Malinda Wu, MD

Eligible Age Range: 5 to 18

Gender: All 

Diagnosis: Osteogenesis Imperfecta